Efficacy of Vitamin D Treatment in Mortality Reduction Due to COVID-19.

Launched by BIOARABA HEALTH RESEARCH INSTITUTE · Nov 6, 2020

Keywords

ClinConnect Summary

HYPOTHESIS: The administration of vitamin D supplements to patients who have a positive diagnosis for SARS-Cov-2, acute pneumonia requiring hospital admission and vitamin D deficiency have a more favourable evolution than subjects not treated with vitamin D (placebo). This favourable evolution will translate into a reduction in mortality, fewer ICU admissions and fewer days of stay in hospital.

OBJECTIVES:

PRINCIPAL: To assess whether the group of patients receiving vitamin D supplements have a less severe evolution of their acute pneumonia, translated into lower mortality, than patients ...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Admitted to the Respiratory or Internal medicine Units of Santiago hospital (HUA) due to pneumonia.
• • Vitamin D deficiency (25(OH) defined by blood levels below 30 mg/ml.
• • Possibility for observation during the treatment period.
• • Signing of written consent (oral informed consent exceptionally).
• • Positive PCR for diagnosis of sars-cov2 infection
• Exclusion Criteria:
• • Patients taking any type of vitamin D supplement.
• • Patients with hypoparathyroidism.
• • Pregnant or lactating women.
• • Patients in whom the administration of vitamin D is formally contraindicated (see annex VI).
• • Patients who at time of inclusion, cannot take vitamin D orally.

Trial Officials